Phase 2 Leukaemia Trial, Recruiting NCT06125652 Sponsor: Xuzhou Medical University Condition: Leukaemia
Back to Leukaemia

Phase 2 Leukaemia Trial, Recruiting

NCT06125652
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 70 years old
  • People who have been diagnosed with relapsed or refractory acute myeloid leukemia (AML) — meaning the leukemia has come back or stopped responding to treatment — whether it developed on its own or as a result of another condition
  • People who have recovered from the side effects of any previous cancer treatments
  • People who are reasonably well and able to carry out daily activities, and whose doctors expect them to live for at least 3 months
  • People whose liver, kidneys, heart, and other organs are working well enough to meet the specific levels required by the trial (confirm exact values with trial site)
  • Women who could become pregnant must have a negative pregnancy test before joining
  • All participants must agree to use effective contraception from the start of treatment until 2 years after treatment ends
  • All participants must sign and date a consent form before any trial-related activities begin

Who may not be able to join:

  • People diagnosed with a specific type of leukemia called acute promyelocytic leukemia
  • People who have a current or past disorder affecting the brain or nervous system
  • People who test positive for Hepatitis B, Hepatitis C, HIV, or Syphilis, or who have a certain level of a virus called CMV detected in their blood
  • People who have had a serious allergic reaction in the past
  • People who have had a heart attack, heart procedure, unstable chest pain, significant heart failure, atrial fibrillation, or other serious heart condition within the 12 months before joining
  • People who have had an organ transplant at any point
  • People who need to take ongoing medications that suppress the immune system
  • People who have had a stem cell transplant using their own cells within the 3 months before joining
  • People with active autoimmune or inflammatory conditions affecting the nervous system, or active conditions affecting blood flow in the brain (confirm specific conditions with trial site)
  • People who need urgent treatment for a serious, immediate complication of their leukemia (confirm with trial site)
  • People who have an active infection that is not under control or that requires ongoing treatment with antimicrobial medicines
  • People who have received a live vaccine within 4 weeks before joining
  • People with a serious mental illness
  • People who have had major surgery within 4 weeks before joining
  • People with a history of alcoholism or drug/substance abuse
  • People considered unsuitable to participate by the investigators for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Kailin Xu, MD.,PD., The Affiliated Hospital oh Xuzhou Medical University

Phone: 15162166166

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Xuzhou Medical University
Registry
ClinicalTrials.gov
Start date
4 November 2023
Est. completion
1 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Dose-limiting toxicity #DLT#

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov